[go: up one dir, main page]

ES2527200T3 - Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana - Google Patents

Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana Download PDF

Info

Publication number
ES2527200T3
ES2527200T3 ES12707135.5T ES12707135T ES2527200T3 ES 2527200 T3 ES2527200 T3 ES 2527200T3 ES 12707135 T ES12707135 T ES 12707135T ES 2527200 T3 ES2527200 T3 ES 2527200T3
Authority
ES
Spain
Prior art keywords
bifidobacteria
oligosaccharides
modulation
growth
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12707135.5T
Other languages
English (en)
Other versions
ES2527200T5 (es
Inventor
David Curtis Frantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2527200(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Publication of ES2527200T3 publication Critical patent/ES2527200T3/es
Application granted granted Critical
Publication of ES2527200T5 publication Critical patent/ES2527200T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulación prebiótica para administración oral a un humano, que lleva 2'-fucosil-lactosa, 6'-sialil-lactosa y 3'- sialil-lactosa y en la cual la proporción en peso de 3'-sialil-lactosa es, como mínimo, igual a la de 2'-fucosil-lactosa.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12707135T 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana Active ES2527200T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441451P 2011-02-10 2011-02-10
US201161441451P 2011-02-10
PCT/IB2012/050511 WO2012107865A2 (en) 2011-02-10 2012-02-03 Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk

Publications (2)

Publication Number Publication Date
ES2527200T3 true ES2527200T3 (es) 2015-01-21
ES2527200T5 ES2527200T5 (es) 2022-12-29

Family

ID=45809349

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12707135T Active ES2527200T5 (es) 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana
ES14177597.3T Active ES2692533T3 (es) 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14177597.3T Active ES2692533T3 (es) 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana

Country Status (19)

Country Link
US (3) US20140371173A1 (es)
EP (2) EP2792252B1 (es)
CN (2) CN103347405A (es)
AU (1) AU2012215042B2 (es)
BR (1) BR112013020108A2 (es)
CA (1) CA2825697A1 (es)
CL (1) CL2013002210A1 (es)
ES (2) ES2527200T5 (es)
IL (1) IL227487A (es)
MX (2) MX345413B (es)
MY (1) MY161034A (es)
PH (1) PH12013501501A1 (es)
PL (1) PL2672844T3 (es)
PT (1) PT2672844E (es)
RU (1) RU2586928C2 (es)
SG (1) SG192095A1 (es)
TW (1) TW201244640A (es)
WO (1) WO2012107865A2 (es)
ZA (1) ZA201306751B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501501A1 (en) 2011-02-10 2019-10-07 Nestec Sa Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
WO2012177556A2 (en) 2011-06-20 2012-12-27 H.J. Heinz Company Probiotic compositions and methods
US20150265661A1 (en) * 2012-04-13 2015-09-24 Trustees Of Boston College Prebiotic effect of sialyllactose
ES2572831T3 (es) 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
EP3129030A1 (en) 2014-04-08 2017-02-15 Abbott Laboratories Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
MX382478B (es) * 2014-10-24 2025-03-13 Infinant Health Inc Bifidobacterias activadas y metodos de uso de las mismas.
CN106998775A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 具有RRR‑α‑生育酚、2’‑岩藻糖基乳糖和益生菌的婴儿配方
EP3223825A1 (en) * 2014-11-26 2017-10-04 Abbott Laboratories Infant formula comprising human milk oligosaccharides, polyunsaturated fatty acids, nucleotides, and lutein
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
CN115350200A (zh) 2014-12-08 2022-11-18 格礼卡姆股份公司 用于治疗代谢障碍的合成组合物
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
MX2017010923A (es) 2015-03-05 2018-01-16 Nestec Sa Composiciones para usar en el mejoramiento de la consistencia o la frecuencia de las heces en infantes o niños pequeños.
PL3368046T3 (pl) 2015-10-28 2022-11-28 Glycom A/S Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania
WO2017071716A1 (en) * 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US11957148B2 (en) * 2015-12-15 2024-04-16 Societe Des Produits Nestle S.A. Mixture of human milk oligosaccharides(HMOs)
LT3471561T (lt) 2016-06-21 2020-08-10 Arla Foods Amba Pagerintų mitybos produktų, turinčių pieno baltymus ir pieno sacharidus, gamybos būdas
RU2019105567A (ru) 2016-07-28 2020-08-28 Фонтерра Ко-Оперэйтив Груп Лимитед Молочный продукт и способ
US11260088B2 (en) 2017-06-21 2022-03-01 Abbott Laboratories Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
WO2019106620A1 (en) * 2017-11-30 2019-06-06 Glycom A/S Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation
US20220241354A1 (en) * 2019-06-05 2022-08-04 Morinaga Milk Industry Co., Ltd. Composition
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260280A (en) 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
BRPI0108478B8 (pt) 2000-02-17 2021-05-25 Nestec Sa composição nutritiva contendo substancias pré-bióticas
WO2001060246A2 (en) * 2000-02-18 2001-08-23 Argose, Inc. Multivariate analysis of green to ultraviolet spectra of cell and tissue samples
US6913778B2 (en) 2001-12-21 2005-07-05 Wyeth Infant formula compositions comprising increased amounts of alpha-lactalbumin
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
PT1638416E (pt) 2003-06-23 2013-07-08 Nestec Sa Utilização de uma fórmula nutricional para função de barreira intestinal óptima
CA2548140A1 (en) 2003-12-05 2005-06-23 University Of Massachusetts Oligosaccharide compositions and use thereof in the treatment of infection
CA2628225C (en) † 2005-11-04 2014-06-17 Hans Henrik Holst A concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof
WO2007114683A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
NL2001377C2 (nl) † 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
SG177541A1 (en) * 2009-07-31 2012-02-28 Nestec Sa Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
NL2004200C2 (en) * 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
EP2563165A1 (en) * 2010-04-27 2013-03-06 N.V. Nutricia Use of 6'-sialyl lactose in infant and toddler nutrition
EP2658402A1 (en) * 2010-12-31 2013-11-06 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
PH12013501501A1 (en) 2011-02-10 2019-10-07 Nestec Sa Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk

Also Published As

Publication number Publication date
AU2012215042B2 (en) 2016-01-14
CL2013002210A1 (es) 2014-01-10
PT2672844E (pt) 2015-02-04
US20140371173A1 (en) 2014-12-18
EP2792252B1 (en) 2018-09-12
ZA201306751B (en) 2015-05-27
MX2013009087A (es) 2013-09-13
RU2013141449A (ru) 2015-03-20
BR112013020108A2 (pt) 2017-06-13
WO2012107865A2 (en) 2012-08-16
TW201244640A (en) 2012-11-16
SG192095A1 (en) 2013-08-30
EP2792252A2 (en) 2014-10-22
EP2672844A2 (en) 2013-12-18
CA2825697A1 (en) 2012-08-16
MY161034A (en) 2017-04-14
PH12013501501A1 (en) 2019-10-07
MX345413B (es) 2017-01-27
US20120208782A1 (en) 2012-08-16
IL227487A0 (en) 2013-09-30
EP2672844B1 (en) 2014-11-19
ES2692533T3 (es) 2018-12-04
EP2672844B2 (en) 2022-10-05
CN104126749A (zh) 2014-11-05
PL2672844T3 (pl) 2015-04-30
RU2586928C2 (ru) 2016-06-10
ES2527200T5 (es) 2022-12-29
IL227487A (en) 2015-10-29
CN103347405A (zh) 2013-10-09
MX362129B (es) 2019-01-07
WO2012107865A3 (en) 2012-11-01
US20150141367A1 (en) 2015-05-21
EP2792252A3 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
ES2527200T3 (es) Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
MX2013007675A (es) Combinacion simbiotica de oligosacaridos probioticos y de leche humana para promover el crecimiento de la microbiota beneficiosa.
DOP2012000324A (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4metil-piperazin-1il)-1h-bencimidazol-2-il)-1h-quinolin-2-ona
MX2023002494A (es) Oligosacaridos de leche humana para modular la inflamacion.
MX2015007933A (es) Oligosacaridos de leche humana para mejorar sintomas de estres.
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
CO6640262A2 (es) Composiciones farmacéuticas y métodos para su elaboración
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
IL239022B (en) Tetracycline topical formulations, preparation and uses thereof
HK1218560A1 (zh) 组成与方法
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CR20130239A (es) Compuestos de triazolopiridina
BR112012019997A2 (pt) composições de cuidado oral
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
BR112016007414A2 (pt) método de produção de um comprimido de monocamada, e, comprimido de monocamada
ES2656474T3 (es) Osteopontina láctea de origen mamífero para potenciar la capacidad de respuesta inmune
ES2616035T3 (es) Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
ES2619428T3 (es) Composición en polvo para desinfección de las ubres de los animales lecheros